Table 2.
Demographics and clinical characteristics
| Patiromer treatment group |
p value* | ||
|---|---|---|---|
| without food (n = 57) | with food (n = 55) | ||
| Age, years, mean (SD) | 66.8 (13.5) | 66.3 (10.3) | 0.832 |
| Age ≥65 years, n (%) | 38 (66.7) | 35 (63.6) | 0.843 |
| Male, n (%) | 40 (70.2) | 33 (60.0) | 0.322 |
| Race, n (%) | |||
| White | 48 (84.2) | 44 (80.0) | 0.864 |
| Black | 6 (l0.5) | 8 (l4.5) | |
| Other | 3 (5.3) | 3 (5.4) | |
| Ethnicity, n (%) | |||
| Hispanic/Latino | 33 (57.9) | 30 (54.5) | 0.849 |
| Non-Hispanic/Latino | 24 (42.l) | 25 (45.5) | |
| Serum K+, mEq/L,† mean (SD) | 5.4 (0.4) | 5.3 (0.4) | 0.166 |
| <5.5, n (%) | 32 (56.1) | 34 (61.8) | 0.570 |
| ≥5.5, n (%) | 25 (43.9) | 21 (38.2) | |
| CKD (all stages), n (%) | 44 (77.2) | 41 (74.5) | 0.827 |
| CKD stages 1–3a | 9 (l5.8) | 7 (l2.7) | 0.785 |
| CKD stages 3b–5 | 35 (61.4) | 34 (61.8) | |
| Diabetes mellitus, n (%) | 48 (84.2) | 44 (80.0) | 0.627 |
| Heart failure, n (%) | 5 (8.8) | 5 (9.1) | 1.000 |
| Hypertension, n (%) | 55 (96.5) | 50 (90.9) | 0.267 |
| RAAS inhibitors, n (%) | 35 (61.4) | 31 (56.4) | 0.701 |
| Beta-blocking agents, n (%) | 28 (49.1) | 30 (54.5) | 0.577 |
| Non-RAAS inhibitor diuretic,‡ n (%) | 18 (31.6) | 22 (40.0) | 0.431 |
CKD, chronic kidney disease; K+, potassium; RAAS, renin-angiotensin aldosterone system.
*
p values for age and serum K+ were based on 2-sample t tests and all other p values were based on Fisher's exact tests.
†
Baseline serum K+ is defined as the mean of serum K+ from the central laboratory on 2 consecutive days (day −1 and day 1) immediately prior to the first dose of patiromer.
‡
All non-RAAS inhibitor diuretics were potassium-wasting.